Evonik Invests $108M in Vancouver GMP Facility

Editor’s Take: British Columbia is home to a fast-growing life sciences sector, where more than 2,000 companies employ close to 20,000 people, most of them in Greater Vancouver.

Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada, which will increase Evonik’s development and manufacturing capacity, helping pharmaceutical and biotech customers bring lipid-based pharmaceutical products from development through commercial scale.

Evonik’s total investment of over 150 million CAD ($108 million) in Vancouver is supported by the Canadian federal government’s Strategic Response Fund with up to 68 million CAD ($49 million). Drug product production is planned to begin at the end of 2029.

“Lipid-based drug delivery technologies are already enabling the next generation of medicines. With the support of the Canadian federal government, this investment builds on our long-standing expertise in the field, enabling the development and commercialization of more life-changing therapies,” said Lauren Kjeldsen, member of Evonik’s Executive Board and COO for the Custom Solutions segment at Evonik.

The project will expand Evonik’s existing manufacturing capabilities through the establishment of a modern GMP facility with more than three times the manufacturing capacity of the current facility for advanced pharmaceutical products. The new facility will also significantly advance quality control (QC) and microbiological testing capabilities, improving efficiency and supporting the timely release of products for clinical use.

More Evonik News

Earlier this year, Evonik announced a $100 million investment over five years to modernize its Lafayette (Tippecanoe), Indiana API manufacturing facility. The company is also investing about EUR 80 million at its Fermas site in Slovenská Ľupča to add downstream fermentation technology.